Company intelligence / Profile preview

Memodyne

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Memodyne is a preclinical-stage biotechnology company focused on developing novel treatments for chronic and neuropathic pain. The company's core technology centers on disrupting the interaction between the tyrosine kinase Src and the NMDA receptor, a key pathway in pain hypersensitivity. By targeting this specific protein-protein interaction rather than blocking the receptor entirely, Memodyne aims to provide effective pain relief without the side effects associated with traditional NMDA antagonists. The company was founded based on research from the Hospital for Sick Children (SickKids) and the University of Toronto.

Therapeutic areas: Neurology
Modalities: PeptidesBiologicSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Memodyne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Memodyne.

Explore the full profile